Thus, in the present study, we performed in silico bioinformatics analyses and experimental validation to identify HNRNPL, PCBP1 and RER1 as novel candidate reference genes, whose expression is predominantly consistent, independent of cancer type, stage, and treatment status, and of patient age and gender. This evidence concerns the gene HNRNPL and cancer.